OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival

Kidney International

Volumn 49, Issue 3, 1996, Pages 768-772

  Abramowicz, Daniel ^a   Norman, Douglas J ^b   Vereerstraeten, Pierre ^b   Goldman, Michel ^b   De Pauw, Luc ^b   Vanherweghem, Jean Louis ^b   Kinnaert, Paul ^b   Kahana, Lawrence ^b   Stuart Jr , Frank P ^b   Thistlethwaite Jr , James R ^b   Shield III, Charles F ^b   Monaco, Anthony ^b   Wu, Shu Chen ^b   Haverty, Thomas P ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; OKT 3;

ADULT; ARTICLE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 9044225150     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1996.106     Document Type: Article

References (38)

1. KUNG P, GOLDSTEIN G, REINHERZ E, SCHLOSSMAN S: Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347-349, 1979
2. ACUTO O, REINHERZ EL: The human T-cell receptor. Structure and function. N Engl J Med 312:1100-1111, 1985
3. KREIS H, LEGENDRE C, CHATENOUD L: OKT3 in organ transplantation. Transplant Rev 5:181-199, 1991
4. ORTHO MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985
5. ABRAMOWICZ D, GOLDMAN M, DE PAUW L, VANHERWEGHEM JL, KINNAERT P, VEREERSTRAETEN P: The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 54:433-437, 1992
6. NORMAN DJ, KAHANA L, STUART FP, THISTLETHWAITE J, SHIELD CF, MONACO A, DEHLINGER J, WU SC, VAN HORN A, HAVERTY TP: A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 55:44-50, 1993
7. COX D, OATES D: Analysis of survival data, in Proportional Hazards Model, London, New York, Chapman and Hall, 1984, pp 91-111
8. ASWAD S, MANN SL, KHETAN U, ASAI P, BOGAARD T, MENDEZ RG, MENDEZ R: Omit HLA matching to attain shorter cold ischemic time? Transplant Proc 25:3053-3055, 1993
9. KUMAR MS, STEPHAN R, CHUI J, BREZIN J, LYONS P, KATZ SM, ABOUNA GM: Comparative study of cadaver donor kidneys preserved in University of Wisconsin solution for less than or longer than 30 hours. Transplant Proc 25:2265-2266, 1993
10. CACCIARELLI T, SUMRANI N, DELANEY V, HONG JH, DIBENEDETTO A, SOMMER BG: The influence of delayed renal allograft function on long-term outcome in the cyclosporine era. Clin Nephrol 39:335-339, 1993
11. MICHAEL HJ, FRANCOS GC, BURKE JF, BESARAB A, MORITZ M, GILLUM D, JARRELL B: A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 48:805-808, 1989
12. CECKA JM, CHO YW, TERASAKI PI: Analyses of the UNOS Scientific Renal Transplant Registry at three years - Early events affecting transplant success. Transplantation 53:59-64, 1992
13. CACCIARELLI TV, SUMRANI N, DIBENEDETTO A, HONG JH, SOMMER BG: The influence of cold ischemia and donor age on renal allograft outcome in the cyclosporine era. Transplant Proc 24:2044-2045, 1992
14. THE CANADIAN MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309:809-815, 1983
15. NOVICK AC, HWEI HH, STEINMULLER D, STREEM SB, CUNNINGHAM RJ, STEINHILBER D, GOORMASTIC M, BUSZTA C: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Transplantation 42:154-158, 1986
16. BERGESE SD, PELLETIER RP, OHYE RG, VALLERA DA, OROSZ CG: Treatment of mice with anti-CD3 mAb induces endothelial vascular cell adhesion molecule-1 expression. Transplantation 57:711-717, 1994
17. SHACKLETON CR, ETTINGER SL, MCLOUGHLIN MG, SCUDAMORE CH, MILLER RR, KEOWN PA: Effect of recovery from ischemic injury on class I and class II MHC antigen expression. Transplantation 49:641-644, 1990
18. SHOSKES DA, HALLORAN PF: Ischemic injury induces altered MHC gene expression in kidney by an interferon-gamma-dependent pathway. Transplant Proc 23:599-601, 1991
19. HALLORAN PF, APRILE MA, FAREWELL V, LUDWIN D, SMITH EK, TSAI SY, BEAR RA, COLE EH, FENTON SS, CATTRAN DC: Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 46:223-228, 1988
20. ABRAMOWICZ D, PRADIER O, MARCHANT A, FLORQUIN S, DE PAUW L, VEREERSTRAETEN P, KINNAERT P, VANHERWEGHEM JL, GOLDMAN M: Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 339:777-778, 1992
21. ABRAMOWICZ D, PRADIER O, DE PAUW L, KINNAERT P, MAT O, SURQUIN M, DOUTRELEPONT J, VANHERWEGHEM J, CAPEL P, VEREERSTRAETEN P, GOLDMAN M: High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 46:1596-1602, 1994
22. ABRAMOWICZ D, DE PAUW L, LE MOINE A, SERMON F, SURQUIN M, DOUTRELEPONT J, ICKX B, DEPIERREUX M, VANHERWEGHEM J, KINNAERT P, GOLDMAN M, VEREERSTRAETEN P: Prevention of OKT3 nephrotoxicity after kidney transplantation. Kidney Int (in press)
23. TOUSSAINT C, DE PAUW L, VEREERSTRAETEN P, KINNAERT P, ABRAMOWICZ D, GOLDMAN M: Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 48:524-526, 1989
24. BATIUK T, BENETT W, NORMAN D: Cytokine nephropathy during anti-lymphocyte therapy. Transplant Proc 25:27-30, 1993
25. ABRAMOWICZ D, SCHANDENE L, GOLDMAN M, CRUSIAUX A, VEREERSTRAETEN P, DE PAUW L, WYBRAN J, KINNAERT P, DUPONT E, TOUSSAINT C: Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 47:606-608, 1989
26. CHATENOUD L, FERRAN C, REUTER A, LEGENDRE C, GEVAERT Y, KREIS H, FRANCHIMONT P, BACH JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 320:1420-1421, 1989
27. SCHROEDER T, FIRST M, MANSOUR R, ALEXANDER J, PENN I: Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kid Dis 14:14-18, 1989
28. BENVENISTY AI, COHEN D, SREGALL MD, HARDY MA: Improved results using OKT3 as induction immunosuppression in renal allografts recipients with delayed graft function. Transplantation 49:321-327, 1990
29. DAFOE D, BROMBERG J, GROSSMAN R, TOMASZEWSKI J, ZMIJEWSKI C, PERLOFF L, NAJI A, ASPLUND M, ALFREY E, SACK M, ZELLERS L, KEARNS J, BARKER C: Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3. Transplantation 51:762-768, 1991
30. CECKA JM, GJERTSON D, TERASAKI PI: Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups? Transplant Proc 25:548-549, 1993
31. FRENKEN LAM, KOENE RAP, TAX WJM: The role of antibody isotype in IFN-γ and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 51:881-887, 1991
32. WAID TH, LUCAS BA, THOMPSON JS, BROWN SA, MUNCH L, PREBECK RJ, JEZEK D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53:80-86, 1992
33. ANASETTI C, MARTIN PJ, STORB R, APPELBAUM FR, BEATTY PG, DAVIS J, DONEY K, HILL HF, STEWART P, SULLIVAN KM, WITHERSPOON RP, THOMAS ED, HANSEN J: Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 54:844-851, 1992
34. ALEGRE ML, PETERSON LJ, XU D, SATTAR HA, JEYARAJAH DR, KOWALKOWSKI K, THISTLETHWAITE JR, ZIVIN RA, JOLLIFFE L, BLUESTONE JA: A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 57:1537-1543, 1994
35. KNIGHT RJ, KURRLE R, MCCLAIN J, RACENBERG J, BAGHDAHSARIAN V, KERMAN R, LEWIS R, VAN BUREN CT, KAHAN BD: Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human α/β-T cell receptor. Transplantation 57:1581-1588, 1994
36. PARLEVLIET KJ, TEN BERGE IJ, YONG SL, SURACHNO J, WILMINK JM, SCHELLEKENS PT: In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 93:2519-2525, 1994
37. KREIS H: Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplant 7:431-446, 1993
38. CHATENOUD L: Immunologic monitoring during OKT3 therapy. Clin Transplant 7:422-430, 1993